Deng, Yuanle
Hu, Han
Jia, Rong
Dai, Wei
Wang, Dengfeng
Zhang, Purong
Zhang, Peng
Cheng, Kai
Tang, Jianning
Wen, Yan
Zhou, Xiang
Shi, Qiuling
Xiong, Zhujuan
Zhou, Jin
Funding for this research was provided by:
Guangdong Association of Clinical Trials (GACT) /Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (YC20210105)
2022CSCO key program (Y-2021AST/zd-0119)
Article History
Received: 22 March 2023
Accepted: 13 April 2023
First Online: 19 May 2023
Declarations
:
: Patients will be invited to participate in the study design, patient recruitment, and study implementation. The general public will not be invited to participate in the study design, recruitment, and implementation. Patients will not be informed of the results of the study unless they request it at the time of enrolment.
: The Ethics Committee for Medical Research and New Medical Technology of Sichuan Cancer Hospital approved this study on June 7, 2022 (No. SCCHEC-02-2022-068), and all methods were carried out in accordance with relevant guidelines and regulations. The manuscript is based on the latest protocol, version 1.0, on May 5, 2022. Any modification to the protocol later will be submitted for subsequent review and approval. Prior to screening, all patients recruited in this study will sign an informed consent form. The results of this study will be disseminated through medical conferences and peer-reviewed publications.
: Not applicable.
: All authors declared that they have no competing interests.